AMPLEX Ankle Fusion and Hindfoot

A Multi-Center, Randomized, Pivotal Study Evaluating AMPLEX Compared To Autogenous Bone Graft in Subjects Indicated for Arthrodesis Surgery Involving the Hindfoot or Ankle

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03028415

Enrollment

Registered

2017-01-23

Start date

2017-07-28

Completion date

2020-07-09

Last updated

2021-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthrodesis Surgery Involving the Hindfoot or Ankle

Brief summary

To demonstrate that AMPLEX is non-inferior to autogenous bone graft (ABG) for bone fusion in a population indicated for single, double, or triple hindfoot arthrodesis or ankle arthrodesis surgery with supplemental graft material.

Interventions

DEVICEAMPLEX

A bone graft substitute

PROCEDUREAutogenous Bone Graft (ABG)

Control material administered by surgical implant

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Signed written informed consent * Indicated for ankle or hindfoot arthrodesis and require one of the following arthrodesis procedures: Tibiotalar (ankle); Talocalcaneal (subtalar); Talonavicular; Calcaneocuboid; Double hindfoot (e.g., talonavicular and talocalcaneal joints); Triple hindfoot (subtalar, talonavicular and calcaneocuboid joints) * Presents with pain on weight-bearing of at least 40 mm on a 100 mm VAS at the area indicated for arthrodesis * Presents with at least one comorbid risk factors that warrant the use of supplemental autogenous bone or allograft: Radiographic evidence of bone defect, deficit, subsidence or subchondral cyst; More than one joint to be fused; Involvement of other adjacent or nonadjacent joints; Large surface area; Intra-articular or extra-articular deformity; Post-traumatic arthritis; Diagnosis of osteoporosis * The Investigator determines if the joint space(s) can be adequately filled with graft material (AMPLEX or ABG) according to the following parameters: Single hindfoot joint fusion: up to 5 cm\^3; Double or triple hindfoot fusion: each individual joint up to 5 cm\^3, but overall, not more than 10 cm3 for the full complement of joints; Ankle fusion: up to 10 cm\^3 * Each fused joint can be rigidly stabilized with with at least 1 and no more than 3 screws across the fusion plane. (Supplemental pins and staples may be used, as well as supplemental screws and plates external to the fusion site(s)) * Willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations * For women of childbearing potential (not post-menopausal for 12 months or surgically sterile), a urine pregnancy test with a negative result must be obtained at screening and within 24 hours prior to procedure. These trial participants must commit to adequate birth control (e.g., oral contraceptive, two methods of barrier birth control, or abstinence) through the 78 week follow-up

Exclusion criteria

* Bone deficit requiring a structural graft * Charcot foot disease * Radiographic evidence of open physes * Prior arthroplasty, arthrodesis, major surgical repair or reconstruction of the index ankle or hindfoot joint(s) * Requires osteotomy or fusion of the midfoot joints * BMI greater than 45 kg/m\^2 * Documented medical history of, or radiographic evidence of, a bone disease (e.g. avascular necrosis) or other condition (e.g., osteolysis) that would preclude the subject from receiving screw fixation in the opinion of the surgeon * Requires intramedullary nail fixation or an external fixator * Comorbidity that would limit the ability to administer any functional measurements such as FAAM-ADL * Has at the time of surgery, a systemic infection or local infection at the site of surgery * Medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., history of transient ischemic attack, stroke or liver disease) * HgbA1c level greater than or equal to 8% * Known hypersensitivity to any of the components of the product \[e.g. B2A peptide, Hydroxyapatite (HA): beta-tricalcium phosphate (βTCP), ceramic granule\] * Currently receiving treatment with a drug known to interfere with bone metabolism \[e.g., systemic corticosteroid therapy (topical corticosteroid therapy is permissible), methotrexate\] * Has previously received treatment with a drug known to interfere with bone metabolism \[e.g., systemic corticosteroid therapy (topical corticosteroid therapy is permissible), methotrexate\] and in the opinion of the investigator could continue to negatively interfere with bone metabolism or bone healing * History of any severe allergy or anaphylaxis, or a history of hypersensitivity to protein pharmaceuticals \[e.g., monoclonal antibodies or gamma globulins, recombinant Bone Morphogenetic Proteins (BMPs)\] * Medical condition requiring radiation, chemotherapy or immunosuppression * Have a prior or active history of malignancy (except for basal cell carcinoma of the skin) * Has a history of autoimmune disease known to affect bone metabolism. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), Juvenile Arthritis, Grave's disease and Hashimoto's thyroiditis; Rheumatoid Arthritis is allowed * Have pathological or genetic liver disease or who have clinically significant, elevated baseline liver function enzymes * Has obvious and/or documented alcohol or illicit drug addictions * Is a prisoner in a correctional institution/facility * Actively involved in litigation or workman's compensation * Has participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 6 months of randomization * Requires chronic therapeutic use of NSAID during the first 6 post-operative weeks (except aspirin up to 325 mg bid for cardiovascular protection and/or DVT prophylaxis) * Has previously been treated with, or exposed to, therapeutic levels of synthetic or recombinant BMPs * Requires chronic subcutaneous or intravenous heparin therapies

Design outcomes

Primary

Measure	Time frame	Description
Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint	At week 52	Proportion of subjects who met all the following criteria for the SPC endpoint at 52 weeks: 1. Improvement in pain on weight-bearing at fusion site (≥20 mm reduction from baseline on 100 mm visual analog scale \[VAS\]); 2. Absence of significant graft harvest site pain (\<20 mm on 100 mm VAS); 3. Improvement in Foot and Ankle Ability Measure Activities of Daily Living subscale (FAAM-ADL) (≥8 points improvement from baseline); 4. Absence of device related or procedure related serious adverse events (up to week 52); 5. Absence of secondary surgical or nonsurgical interventions intended to promote fusion (up to week 52). The last observation carried forward was used for subjects with missing response status at 52 weeks.

Secondary

Measure	Time frame	Description
Proportion of Subjects Achieving CT Radiographic Fusion Success	At week 12	Defined as ≥50% bone bridging across the joint space for the full complement of joints in the absence of secondary surgical or nonsurgical interventions intended to promote fusion.
Proportion of Subjects With Change From Baseline in Pain on Weight-bearing at Fusion Site (>20 mm Reduction From Baseline on 100 mm VAS)	Baseline, and at week 12	Weight-bearing pain at the fusion site was assessed using a 100 mm visual analog scale (VAS), a subject self-assessment questionnaire. Subjects were asked to mark the location on a 100 mm line corresponding to the amount of pain they experienced, with 0 mm being no pain and 100 mm being the worst pain imaginable. Improvement in pain on weight-bearing at the fusion site was defined as ≥ 20 mm reduction from baseline on 100 mm VAS, and is presented for this outcome measure.
Proportion of Subjects With Absence of Graft Harvest Site Pain (<20 mm on 100 mm VAS)	At week 2	Graft harvest site pain was assessed using a 100 mm visual analog scale (VAS), a subject self-assessment questionnaire, and was only assessed among subjects in the ABG group. Subjects in the ABG group were asked to mark the location on a 100 mm line corresponding to the amount of pain they experienced with 0 mm being no pain and 100 mm being the worst pain imaginable. Absence of significant graft harvest site pain was defined as \<20 mm on 100 mm VAS, and is presented for this outcome measure.
Proportion of Subjects Achieving Computerized Tomography (CT) Radiographic Fusion Success	At week 52	Defined as ≥50% bone bridging across the joint space for the full complement of joints in the absence of secondary surgical or nonsurgical interventions intended to promote fusion. The last observation carried forward was used for subjects with missing response status at 52 weeks.
Subject Performance Composite (SPC) Endpoint	At week 12	Proportion of subjects who met all the following criteria for the Subject Performance Composite (SPC) endpoint at 12 weeks: 1. Improvement in pain on weight-bearing at fusion site (≥20 mm reduction from baseline on 100 mm visual analog scale \[VAS\]); 2. Absence of significant graft harvest site pain (\<20 mm on 100 mm VAS); 3. Improvement in Foot and Ankle Ability Measure Activities of Daily Living subscale (FAAM-ADL) (≥8 points improvement from baseline); 4. Absence of device related or procedure related serious adverse events (up to week 12); 5. Absence of secondary surgical or nonsurgical interventions intended to promote fusion (up to week 12).
Change From Baseline in Short Form-12 (SF-12)	Baseline, and at week 24	The Short Form-12 (SF-12) Health Survey includes 12 questions from the SF-36 Health Survey. These include: 2 questions concerning physical functioning; 2 questions on role limitations because of physical health problems; 1 question on bodily pain; 1 question on general health perceptions; 1 question on vitality (energy/fatigue); 1 question on social functioning; 2 questions on role limitations because of emotional problems; and 2 questions on general mental health (psychological distress and psychological well-being). These eight domain scales were used to derive Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. All scores were calculated through scoring software. Domain scales and component summary scores ranged from 0 to 100, with a higher score considered better.
Change From Baseline in FAAM-ADL	Baseline, and at week 12	Functional improvement was assessed using the Foot and Ankle Ability Measure Activities of Daily Living (FAAM-ADL) subscale, a subject self-assessment questionnaire that consists of 21 items pertaining to basic functional activities. Each item is scored on a 5 point Likert scale anchored by 4 (no difficulty at all) and 0 (unable to do). The total item subscale score ranges from 0 to 84, which are transformed to a scale of 0 to 100 as the final score. Higher scores represent a higher level of function, with 100 representing no dysfunction.

Countries

Canada, United States

Participant flow

Recruitment details

The trial was conducted at 19 sites (14 sites in the United States and 5 sites in Canada) between July 2017 to July 2020.

Pre-assignment details

A total of 80 subjects were screened in the trial, of which, 56 subjects were randomized. All the 56 randomized subjects were exposed to graft material: 39 subjects were exposed to AMPLEX and 17 subjects were exposed to autogenous bone graft (ABG).

Participants by arm

Arm	Count
AMPLEX AMPLEX: A bone graft substitute	39
Autogenous Bone Graft (ABG) Autogenous Bone Graft (ABG): Control material administered by surgical implant	17
Total	56

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Discontinued due to COVID-19	1	0
Overall Study	Lost to Follow-up	6	3
Overall Study	Withdrawal by Subject	1	0

Baseline characteristics

Characteristic	AMPLEX	Autogenous Bone Graft (ABG)	Total
Age, Continuous	55.4 years STANDARD_DEVIATION 12	50.5 years STANDARD_DEVIATION 14.4	53.9 years STANDARD_DEVIATION 12.8
Age, Customized <65 years	29 participants	14 participants	43 participants
Age, Customized >=65 years	10 participants	3 participants	13 participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	1 Participants	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	39 Participants	16 Participants	55 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	2 Participants	2 Participants
Race (NIH/OMB) Asian	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Black or African American	2 Participants	3 Participants	5 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants	0 Participants	1 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	36 Participants	12 Participants	48 Participants
Region of Enrollment Canada	20 participants	7 participants	27 participants
Region of Enrollment United States	19 participants	10 participants	29 participants
Sex: Female, Male Female	18 Participants	13 Participants	31 Participants
Sex: Female, Male Male	21 Participants	4 Participants	25 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 39	0 / 17
other Total, other adverse events	27 / 39	12 / 17
serious Total, serious adverse events	7 / 39	7 / 17

Outcome results

Primary

Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint

Proportion of subjects who met all the following criteria for the SPC endpoint at 52 weeks: 1. Improvement in pain on weight-bearing at fusion site (≥20 mm reduction from baseline on 100 mm visual analog scale \[VAS\]); 2. Absence of significant graft harvest site pain (\<20 mm on 100 mm VAS); 3. Improvement in Foot and Ankle Ability Measure Activities of Daily Living subscale (FAAM-ADL) (≥8 points improvement from baseline); 4. Absence of device related or procedure related serious adverse events (up to week 52); 5. Absence of secondary surgical or nonsurgical interventions intended to promote fusion (up to week 52). The last observation carried forward was used for subjects with missing response status at 52 weeks.

Time frame: At week 52